Deakin University
Browse

Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells

Download (2.83 MB)
Version 3 2024-06-18, 03:01
Version 2 2024-06-03, 06:57
Version 1 2017-07-24, 16:14
journal contribution
posted on 2024-06-18, 03:01 authored by H Alshamaileh, T Wang, D Xiang, W Yin, PHL Tran, RA Barrero, PZ Zhang, Y Li, Lingxue KongLingxue Kong, K Liu, SF Zhou, Y Hou, Sarah ShigdarSarah Shigdar, Wei DuanWei Duan
AbstractThe development of chemoresistance and inability in elimination of cancer stem cells are among the key limitations of cancer chemotherapy. Novel molecular therapeutic strategies able to overcome such limitations are urgently needed for future effective management of cancer. In this report, we show that EpCAM-aptamer-guided survivin RNAi effectively downregulated survivin both in colorectal cancer cellsin vitroand in a mouse xenograft model for colorectal cancer. When combined with the conventional chemotherapeutic agents, the aptamer-guided survivin RNAi was able to enhance the sensitivity towards 5-FU or oxaliplatin in colorectal cancer stem cells, increase apoptosis, inhibit tumour growth and improve the overall survival of mice bearing xenograft colorectal cancer. Our results indicate that survivin is one of the key players responsible for the innate chemoresistance of colorectal cancer stem cells. Thus, aptamer-mediated targeting of survivin in cancer stem cells in combination with chemotherapeutic drugs constitutes a new avenue to improve treatment outcome in oncologic clinics.

History

Journal

Scientific Reports

Volume

7

Article number

ARTN 5898

Pagination

1 - 9

Location

England

Open access

  • Yes

ISSN

2045-2322

eISSN

2045-2322

Language

English

Publication classification

C Journal article, C1 Refereed article in a scholarly journal

Copyright notice

2017, The Authors

Issue

1

Publisher

NATURE PUBLISHING GROUP